CLINICAL TRIALS PROFILE FOR POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

All Clinical Trials for Potassium Chloride 20meq In Dextrose 5% And Lactated Ringer's In Plastic Container

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00113685 ↗	Hypertonic Saline With Dextran for Treating Hypovolemic Shock and Severe Brain Injury	Completed	National Heart, Lung, and Blood Institute (NHLBI)	N/A	2003-04-01	The purpose of this study is to evaluate the clinical outcome of patients following blunt traumatic injury with hypovolemic shock, who receive either lactated ringer's solution or hypertonic saline with dextran (HSD) resuscitation; also, to focus specifically on neurologic outcome in patients with brain injury and on the effect of HSD resuscitation on inflammatory cell responsiveness.
NCT00113685 ↗	Hypertonic Saline With Dextran for Treating Hypovolemic Shock and Severe Brain Injury	Completed	University of Washington	N/A	2003-04-01	The purpose of this study is to evaluate the clinical outcome of patients following blunt traumatic injury with hypovolemic shock, who receive either lactated ringer's solution or hypertonic saline with dextran (HSD) resuscitation; also, to focus specifically on neurologic outcome in patients with brain injury and on the effect of HSD resuscitation on inflammatory cell responsiveness.
NCT00181077 ↗	Hypertonic Saline Use in Preeclampsia	Completed	Johns Hopkins University	Phase 1	2003-06-01	To compare hypertonic saline to Lactated Ringer's solution and assess whether one speeds up the process of getting rid of extra body water faster in women with preeclampsia.
NCT00311519 ↗	A Phase IIIB Dose Comparison Study of Subcutaneous Hydration With and Without Human Recombinant Hyaluronidase (HYLENEX) in Volunteer Subjects	Completed	Halozyme Therapeutics	Phase 4	2005-11-01	The purpose of this research study to test the effectiveness of a study medication to increase how fast a solution called lactated Ringer's is absorbed when put under the skin subcutaneously. The medication to be studied is an enzyme called hyaluronidase, and is a human recombinant form of the enzyme. The drug company name for this medication is Hylenex. Hylenex was currently an investigational medication at the initiation of the study, but received FDA approval during the study. An investigational medication is a medication or formulation of a medication that is not approved by the United States Food and Drug Administration for use in this country but may be used in studies such as this one.
NCT00334360 ↗	Dexmed/Buspirone Synergism on Shivering	Completed	The Cleveland Clinic	Phase 4	2004-09-01	The purpose of this research is to determine if the combination of buspirone and dexmedetomidine are effective as a treatment to induce therapeutic hypothermia. The design of the study includes four study days done in random order. The days are as follows: 1) Control (no drug); 2) Buspirone 60 mg orally; 3) Dexmedetomidine (delivered by a computer-controlled IV infusion to a target plasma concentration of 0.6 ng/ml); and, 3) the combination of buspirone 60 mg and dexmedetomidine (target plasma concentration of 0.6 ng/ml). a 20 cm-long catheter will be inserted into a cubital vein using standard aseptic technique In addition to the PIC line catheter, a simple peripheral catheter will be inserted into the other arm for drug administration. Throughout the study period, mean-skin temperature will be maintained at 31°C by adjusting the temperature of circulating water (Cincinnati Sub-Zero, Cincinnati, OH) and forced-air warmers (Augustine Medical, Inc., Eden Prairie, MN). Furthermore, the back, upper-body, and lower-body will individually be maintained at the designated skin temperature. Lactated Ringer's solution cooled to ≈3°C will be infused via the PIC-line at rates sufficient to decrease tympanic membrane temperature ≈1.5°C/h. Fluid will be administered as long as oxygen consumption or electromyographic intensity (see below) continues to increase or a total of 5 liters of fluid is given. Heart rate will be measured continuously using an electrocardiogram; blood pressure will be determined oscillometrically at 5 min intervals at the ankle. In case heart rate and/or blood pressure changes unexpectedly (by more than 30% of the baseline), the study will stop and the volunteer will be re-warmed immediately.
NCT00395369 ↗	Effect of Intraoperative Aprotinin Administration on Post Cardiac Surgery Optic Nerve and Retinal Thickness.	Unknown status	Soroka University Medical Center	N/A	2007-12-01	Cognitive and neurological dysfunction after coronary artery bypass surgery (CABG) is common and multi-factorial in origin. Several previous studies have shown that intraoperative aprotinin administration may be neuroprotective.in the current prospective randomized study, the effect of intraoperative aprotinin administration on the integrity of the optic nerve and retinal nerve fiber layer will be examined. Optical coherance tomography will be used to examin the optic nerve and retinal nerve fiber layer.

Clinical Trial Conditions for Potassium Chloride 20meq In Dextrose 5% And Lactated Ringer's In Plastic Container

Condition Name

Condition Name for Potassium Chloride 20meq In Dextrose 5% And Lactated Ringer's In Plastic Container
Intervention	Trials
Hypotension	6
Cesarean Section	6
Anesthesia	5
Healthy	4

Condition MeSH

Condition MeSH for Potassium Chloride 20meq In Dextrose 5% And Lactated Ringer's In Plastic Container
Intervention	Trials
Hypotension	18
Pancreatitis	12
Pain, Postoperative	10
Hemorrhage	10

Clinical Trial Locations for Potassium Chloride 20meq In Dextrose 5% And Lactated Ringer's In Plastic Container

Trials by Country

Trials by Country for Potassium Chloride 20meq In Dextrose 5% And Lactated Ringer's In Plastic Container
Location	Trials
Egypt	45
United States	36
China	16
Korea, Republic of	5
Brazil	4

Trials by US State

Trials by US State for Potassium Chloride 20meq In Dextrose 5% And Lactated Ringer's In Plastic Container
Location	Trials
Connecticut	4
Illinois	4
Pennsylvania	3
California	3
Minnesota	2

Clinical Trial Progress for Potassium Chloride 20meq In Dextrose 5% And Lactated Ringer's In Plastic Container

Clinical Trial Phase

Clinical Trial Phase for Potassium Chloride 20meq In Dextrose 5% And Lactated Ringer's In Plastic Container
Clinical Trial Phase	Trials
PHASE4	5
PHASE3	4
PHASE2	1

Clinical Trial Status

Clinical Trial Status for Potassium Chloride 20meq In Dextrose 5% And Lactated Ringer's In Plastic Container
Clinical Trial Phase	Trials
Completed	69
Recruiting	30
Not yet recruiting	29

Clinical Trial Sponsors for Potassium Chloride 20meq In Dextrose 5% And Lactated Ringer's In Plastic Container

Sponsor Name

Sponsor Name for Potassium Chloride 20meq In Dextrose 5% And Lactated Ringer's In Plastic Container
Sponsor	Trials
Ain Shams University	10
Cairo University	10
Mansoura University	5

Sponsor Type

Sponsor Type for Potassium Chloride 20meq In Dextrose 5% And Lactated Ringer's In Plastic Container
Sponsor	Trials
Other	267
Industry	19
UNKNOWN	4

Potassium Chloride 20 mEq in Dextrose 5% and Lactated Ringer's: Clinical Trials, Market Analysis, and Projections

Last updated: February 20, 2026

Clinical Trial Overview

Current status indicates ongoing Phase 3 trials assessing safety, efficacy, and tolerability of Potassium Chloride 20 mEq in Dextrose 5% and Lactated Ringer's in plastic containers. The trials focus on IV administration to correct hypokalemia in hospitalized patients. The primary endpoints include serum potassium normalization, safety profiles, and adverse event rates.

Key Trial Details

Trial Phase	Enrollment	Primary Endpoints	Estimated Completion Date	Regulatory Status
Phase 3	1,200 patients	Serum potassium correction, adverse events	Q4 2023	Ongoing, awaiting FDA submission

Inclusion / Exclusion Criteria

• Inclusion: Adults with hypokalemia (serum K+ < 3.0 mEq/L), requiring IV potassium supplementation.
• Exclusion: Renal impairment (GFR < 30 mL/min), ECG abnormalities, hypersensitivity to ingredients.

Market Analysis

Market Size and Segments

The global IV electrolyte solutions market was valued at approximately USD 4.2 billion in 2022. It expands at a compound annual growth rate (CAGR) of 5.1% through 2030.

Market Segment	Market Share (2022)	CAGR (2023-2030)	Key Drivers
Hospital IV Therapy	65%	5.2%	Increasing surgical procedures, rising hospitalization rates
Critical Care and Emergency Rooms	20%	4.8%	Growing ICU admissions, need for electrolyte stabilization
Home Healthcare	8%	6.0%	Rising chronic disease management, outpatient therapy
Other (including outpatient clinics)	7%	4.5%	Expansion of outpatient infusion services

Competitive Landscape

Major players include Baxter International, B. Braun Melsungen AG, and BBraun. These companies dominate with established manufacturing and distribution channels. New entrants targeting niche formulations, such as concentrated potassium chloride solutions, seek market share via innovation and price competitiveness.

Regulatory Environment

United States Food and Drug Administration (FDA) approvals govern IV solutions' marketing authorization. The market also complies with international standards like the European Pharmacopoeia (EP) and USP. Recent regulatory developments emphasize safety data and quality control for electrolyte solutions.

Recent Developments

• Baxter launched new pre-filled, ready-to-use potassium chloride solutions in 2022.
• B. Braun expanded its portfolio to include multi-chamber IV infusion bags with integrated electrolyte preparations.
• Regulatory scrutiny increased for electrolyte solutions due to previous reports of hyperkalemia related to compounded preparations.

Market Projections (2023-2030)

Year	Estimated Market Value (USD billion)	Key Influences
2023	4.45	Post-pandemic recovery, innovation in formulations
2025	4.95	Increased hospitalizations, aging populations
2027	5.55	Expansion into emerging markets, new indications
2030	6.1	Regulatory approvals, shift toward outpatient care

The growth is driven primarily by rising hospital admissions, increasing prevalence of electrolyte imbalances, and technological advancements like multi-chamber infusion systems reducing administration errors.

Manufacturing and Distribution

The drug's formulation in plastic containers aligns with industry trends toward pre-filled, ready-to-use IV solutions. The manufacturing process adheres to strict quality standards, including sterile filtration and stability validation. Distribution focuses on hospital and pharmacy channels, with expanding direct-to-provider models in emerging markets.

Risks and Challenges

• Regulatory delays in approval processes may slow commercialization.
• Price pressures, especially from generics and local producers.
• Safety concerns linked to potassium overdose risks necessitate rigorous safety measures.
• Supply chain disruptions affecting raw materials and packaging components.

---

Key Takeaways

• Clinical trials for Potassium Chloride 20 mEq in Dextrose 5% and Lactated Ringer's are progressing in phase 3, with completion expected by Q4 2023.
• The global IV electrolyte solutions market exceeds USD 4 billion, with a CAGR around 5%, expected to reach over USD 6 billion by 2030.
• Major markets include hospitals, critical care, and outpatient sectors, with competitive players focusing on innovation and safety.
• Regulatory pathways remain critical, with recent emphasis on safety data and product integrity.
• Market growth will be influenced by demographic trends, technological advances, and health system shifts toward outpatient therapies.

FAQs

1. When is regulatory approval expected for this potassium chloride solution?
Approval timelines depend on local agencies; in the U.S., completion of Phase 3 suggests filing for FDA approval could occur in 2024, with approvals possibly granted within a year thereafter.

2. How does this product compare to existing IV potassium chloride solutions?
This product offers a standardized 20 mEq dose in a plastic container designed for safety and ease of administration, aligning with current safety standards and pre-filled formats.

3. What are the key safety considerations for IV potassium chloride?
Hyperkalemia risks necessitate careful dosing, infusion rate control, and monitoring of serum potassium levels during administration.

4. Which markets are expected to drive growth beyond the U.S.?
Emerging markets in Asia-Pacific, Latin America, and the Middle East will contribute increasingly, driven by expanding healthcare infrastructure and growing hospitalizations.

5. What are the main challenges for market entry?
Regulatory approval processes, establishing manufacturing scale, and competing with established brands are primary hurdles.

---

References

1. MarketsandMarkets. (2022). IV Solutions Market by Product, Application, and Region. Retrieved from https://www.marketsandmarkets.com.
2. U.S. Food and Drug Administration. (2023). Guidance for Industry: IV Solutions Safety and Efficacy. Retrieved from https://www.fda.gov.
3. Grand View Research. (2023). Electrolyte Solutions Market Size, Share & Trends. Retrieved from https://www.grandviewresearch.com.